Document is current
Any future updates will be listed below
-
Authors
Sommerlath, Vivien N.
Buergy, Daniel
Etminan, Nima
Brehmer, Stefanie
Reuss, David
Sarria, Gustavo R.
Guiot, Marie-Christin
Hänggi, Daniel
Wenz, Frederik
Petrecca, Kevin
Giordano, Frank A. https://orcid.org/0000-0001-5243-4781
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB1389 (UNITE Glioblastoma))
Universitätsklinikum Bonn
- License Information
-
More Information
Article History
Received: 28 June 2021
Accepted: 9 January 2022
First Online: 24 January 2022
Declarations
:
: The study was approved by the ethics committee of Heidelberg University, Medical Faculty Mannheim (2013-832R-MA). Written informed consent for scientific usage of clinical data was obtained from all patients.
: Not applicable.
: DB reports personal fees from NB Capital ApS, personal fees from Nordic Biotech, personal fees from Siemens AG, personal fees from b.e. Imaging GmbH, outside the submitted work; FG reports research grants and travel expenses from ELEKTA AB; grants, stocks, travel expenses and honoraria from NOXXON Pharma AG; research grants, travel expenses and honoraria from Carl Zeiss Meditec AG; travel expenses and honoraria from Bristol-Myers Squibb, Roche Pharma AG, MSD Sharp and Dohme GmbH and AstraZeneca GmbH; non-financial support from Oncare GmbH and Opasca GmbH. GRS: Grants and personal fees from Carl Zeiss Meditec AG; personal fees from Roche Pharma AG. All other authors report no conflicts of interest.
